185 related articles for article (PubMed ID: 33260593)
21. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure.
Schiffrin EL; Larivière R; Li JS; Sventek P
J Vasc Res; 1996; 33(3):235-48. PubMed ID: 8924521
[TBL] [Abstract][Full Text] [Related]
22. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
23. Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats.
Galisteo M; García-Saura MF; Jiménez R; Villar IC; Zarzuelo A; Vargas F; Duarte J
Mol Cell Biochem; 2004 Apr; 259(1-2):91-9. PubMed ID: 15124912
[TBL] [Abstract][Full Text] [Related]
24. Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension.
Adeagbo AS; Zhang X; Patel D; Joshua IG; Wang Y; Sun X; Igbo IN; Oriowo MA
J Hypertens; 2005 May; 23(5):1025-36. PubMed ID: 15834289
[TBL] [Abstract][Full Text] [Related]
25. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats.
Kobayashi N; Mori Y; Nakano S; Tsubokou Y; Shirataki H; Matsuoka H
J Hypertens; 2001 Apr; 19(4):795-801. PubMed ID: 11330883
[TBL] [Abstract][Full Text] [Related]
26. Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice.
Cao HJ; Fang J; Zhang YL; Zou LX; Han X; Yang J; Yan X; Li PB; Wang HX; Guo SB; Li HH
J Mol Cell Cardiol; 2019 Dec; 137():34-45. PubMed ID: 31629736
[TBL] [Abstract][Full Text] [Related]
27. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
29. Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil.
Galisteo M; García-Saura MF; Jiménez R; Villar IC; Wangensteen R; Zarzuelo A; Vargas F; Duarte J
Planta Med; 2004 Apr; 70(4):334-41. PubMed ID: 15095149
[TBL] [Abstract][Full Text] [Related]
30. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
O'Brien D; Chunduri P; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):296-301. PubMed ID: 20041879
[TBL] [Abstract][Full Text] [Related]
31. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats.
Gutkind JS; Kurihara M; Saavedra JM
Am J Physiol; 1988 Sep; 255(3 Pt 2):H646-50. PubMed ID: 3414825
[TBL] [Abstract][Full Text] [Related]
32. Macrophage-dependent impairment of α
Mui RK; Fernandes RN; Garver HG; Van Rooijen N; Galligan JJ
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H863-H877. PubMed ID: 29351460
[TBL] [Abstract][Full Text] [Related]
33. Effects of alpha-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats.
Takaoka M; Kobayashi Y; Yuba M; Ohkita M; Matsumura Y
Eur J Pharmacol; 2001 Jul; 424(2):121-9. PubMed ID: 11476758
[TBL] [Abstract][Full Text] [Related]
34. Captopril Alleviates Chondrocyte Senescence in DOCA-Salt Hypertensive Rats Associated with Gut Microbiome Alteration.
Chan LC; Zhang Y; Kuang X; Koohi-Moghadam M; Wu H; Lam TYC; Chiou J; Wen C
Cells; 2022 Oct; 11(19):. PubMed ID: 36231135
[TBL] [Abstract][Full Text] [Related]
35. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
36. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.
Li JS; Larivière R; Schiffrin EL
Hypertension; 1994 Aug; 24(2):183-8. PubMed ID: 8039842
[TBL] [Abstract][Full Text] [Related]
37. The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension.
Ndisang JF; Jadhav A
Am J Physiol Regul Integr Comp Physiol; 2010 Jan; 298(1):R211-23. PubMed ID: 19864334
[TBL] [Abstract][Full Text] [Related]
38. Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
Fujita K; Matsumura Y; Miyazaki Y; Takaoka M; Morimoto S
Jpn J Pharmacol; 1996 Apr; 70(4):313-9. PubMed ID: 8774759
[TBL] [Abstract][Full Text] [Related]
39. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats.
Jin L; Beswick RA; Yamamoto T; Palmer T; Taylor TA; Pollock JS; Pollock DM; Brands MW; Webb RC
J Physiol Pharmacol; 2006 Sep; 57(3):343-57. PubMed ID: 17033089
[TBL] [Abstract][Full Text] [Related]
40. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat.
Beswick RA; Dorrance AM; Leite R; Webb RC
Hypertension; 2001 Nov; 38(5):1107-11. PubMed ID: 11711506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
